Dasatinib-related resistance frequently occurs and may lead to the failure of chemotherapy; thus, dose interruptions are necessary. Cannabidiol (CBD) has potential for integration with orthodox cancer care. In this study, we explored the combination effect of CBD and dasatinib on A549 cells. CBD in combination with dasatinib could induce significant synergistic apoptosis in vitro (ZIP > 10) and in vivo. The combination of CBD and low-dose dasatinib exhibited antiproliferative and proapoptotic effects through up-regulation of caspase-3 and Bax, and down-regulation of Bcl-2 in A549 cells. The xenograft mouse model suggested that the combination was more efficient and safer. In short, CBD and low-dose dasatinib exhibited a synergistic effect on anticancer by targeting the SRC/PI3K/AKT signaling pathway, suggesting a potential therapeutic option for the treatment of lung cancer.
Multiple myeloma (MM) is a malignancy of plasma cells that leads to marrow failure and bone lesions. Numerous studies have verified the link between long non‑coding RNAs (lncRNAs) and MM. The present study aimed to examine the role and underlying mechanism of differentiation antagonizing non‑protein coding RNA (DANCR) in MM cells. The relative expression levels of DANCR, microRNA (miR)‑135b‑5p and Krüppel‑like factor 9 (KLF9) were examined using reverse transcription‑quantitative PCR. Cell viability was assessed using the MTT assay, while relative cell migration and invasion were evaluated using Transwell assays. Moreover, the dual‑luciferase reporter assay was used to examine the interplay between DANCR, miR‑135b‑5p and KLF9. Western blotting was performed to determine the expression level of KLF9. It was found that lncRNA DANCR and KLF9 were downregulated, while miR‑135b‑5p was upregulated in the serum of patients with MM and in MM cells compared with the controls. Overexpressing DANCR or knocking down miR‑135b‑5p reduced the viability of the MM cells, as well as restrained MM cells from migrating and invading. Furthermore, DANCR directly targeted miR‑135b‑5p and was negatively correlated with miR‑135b‑5p. It was also found that KLF9 was targeted by miR‑135b‑5p and was inversely correlated with miR‑135b‑5p expression. The impact of lncRNA DANCR‑mediated suppression on cell viability, invasion and migration was partially abolished by short hairpin RNA KLF9 or miR‑135b‑5p mimics transfection in MM cells. Thus, it was suggested that lncRNA DANCR repressed the viability, migration and invasion of MM cells by sponging miR‑135b‑5p to target KLF9.
Multiple myeloma (MM) is a hematologic malignancy driven by clonal plasma-cell proliferation and remains largely incurable owing to disease relapse and acquired drug resistance. Ferroptosis, an iron-dependent form of regulated cell death characterized by excessive lipid peroxidation, has emerged as a potential therapeutic target in cancer and is increasingly implicated in MM biology. Unlike apoptosis and other classical cell death pathways, ferroptosis is closely associated with dysregulated iron metabolism, oxidative stress, and lipid peroxidation, all of which are key features of MM biology. This review first outlines the molecular mechanisms of ferroptosis and then summarizes current evidence linking ferroptosis to MM progression, therapeutic resistance, and emerging therapeutic strategies. In addition, current therapeutic strategies targeting ferroptosis are discussed, including inhibition of system Xc−, direct targeting of GPX4, modulation of iron metabolism, and their potential synergistic effects with existing anti-myeloma therapies. Finally, the major challenges associated with clinical translation are highlighted, together with future directions for biomarker development and ferroptosis-based therapeutic strategies. Collectively, ferroptosis represents a promising therapeutic concept for exploiting redox and metabolic vulnerabilities in MM. Nevertheless, current knowledge is derived predominantly from preclinical studies, and successful clinical translation will require improved tumor selectivity, rigorous safety evaluation, and biomarker-guided patient stratification.
The methodologies and applications of ex vivo expansion of umbilical cord blood cells represent a significant research domain, primarily owing to the distinctive characteristics of these cells and their prospective uses in regenerative medicine and hematopoietic stem cell transplantation. We searched PubMed and Web of Science using the terms “umbilical cord blood cells,” “cytokine,” “haematopoietic cells,” “umbilical cord mesenchymal stem cells,” “in vitro expansion,” and “microenvironment,” and the selected literature was organized and analyzed. We present a narrative review of the mechanisms by which umbilical cord mesenchymal stem cells enhance the in vitro expansion of umbilical cord blood-derived hematopoietic stem cells, focusing on three primary aspects: secretion of diverse cytokines to replicate the natural hematopoietic microenvironment, transmission of critical signals via direct cell-to-cell contact, and exertion of immunomodulatory effects to alleviate environmental stress. Although these processes can significantly promote the proliferation and survival of hematopoietic stem cells, the challenge of concurrently preserving the long-term stemness of these cells in an in vitro environment remains a critical issue for future research.